US 12,337,016 B2
Composition for preventing or treating ocular diseases comprising amniotic epithelial cell derived exosomes
Hong Kyun Kim, Daegu (KR)
Assigned to KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
Appl. No. 17/787,603
Filed by KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR)
PCT Filed Mar. 22, 2021, PCT No. PCT/KR2021/003470
§ 371(c)(1), (2) Date Jun. 21, 2022,
PCT Pub. No. WO2021/230487, PCT Pub. Date Nov. 18, 2021.
Claims priority of application No. 10-2020-0056647 (KR), filed on May 12, 2020.
Prior Publication US 2022/0409671 A1, Dec. 29, 2022
Int. Cl. A61K 35/50 (2015.01); A61P 27/02 (2006.01)
CPC A61K 35/50 (2013.01) [A61P 27/02 (2018.01)] 8 Claims
 
1. A method of treating an ocular disease, comprising:
administering a pharmaceutical composition comprising amniotic epithelial cell-derived exosomes as an active ingredient to a subject,
wherein the pharmaceutical composition comprising the amniotic epithelial cell-derived exosomes treats the ocular disease which is an ocular surface disease selected from the group consisting of dry eye syndrome, corneal epithelial damage, keratitis, conjunctivitis, and keratoconjunctivitis.